GB001 in Adult Subjects With Moderate to Severe Asthma
What is the purpose of this trial?
A randomized, double-blind, placebo-controlled, dose-ranging, multi-center study to evaluate the efficacy and safety of GB001 when added to standard-of care (SOC) asthma maintenance therapy in adults with moderate to severe asthma and an eosinophilic phenotype with respect to asthma worsening at the end of 24 weeks of treatment.
- Ages18 - 74 years
- Trial withGossamer Bio, Inc.
- Start Date07/21/2019
- End Date06/29/2020
- Last Updated08/05/2019
- Study HIC#2000024277